New research reaffirms that GLP-1s can help prevent heart attacks, but only as long as you're taking them.
The companies' new partnership could signal the beginning of the end for compounded GLP-1s.
A new review finds no convincing evidence that drugs like Ozempic raise people's risk of common thyroid cancers.
Poison control calls involving GLP-1 medications like semaglutide and tirzepatide have dramatically risen in recent years.
Monthly injections, once-daily pills, and even lifelong gene therapies could soon become options for people looking to lose some weight.
Novo Nordisk is worried about competition and wants to be seen as the cool kid... by using a 20-year-old ad format.
People taking an obesity drug typically regain weight, a new review finds, often even quicker than people who lose weight through lifestyle changes alone.
Despite everything, science goes on.
New research finds that people taking GLP-1 tend to spend less money grocery shopping, especially on snacks.
Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
A new study finds a possible association between GLP-1 drugs like semaglutide and chronic cough, though the authors are calling for more research.
New research suggests that people taking GLP-1 therapy are less likely to die from colorectal cancer.
Preliminary research suggests that NG101, a drug from Neurogastrx, may lower the risk of nausea and vomiting in people taking semaglutide.
Man down in the Oval Office.
A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.
New findings offer a hint as to why people taking these obesity medications also tend to report drinking less.
Researchers investigated why some people don’t respond as well to GLP-1 drugs and found that the reasons behind their overeating might play a role.
Semaglutide and tirzepatide are among 20 new additions to the WHO's list of essential medicines.
In new Phase III trial data released Tuesday, people taking orforglipron lost substantially more weight than people taking a placebo.
The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.
